"Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of HIV Units."

NAActive, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

April 21, 2025

Study Completion Date

July 15, 2025

Conditions
HIV Infections
Interventions
OTHER

DAY HOSPITAL ARM

"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."

OTHER

Specialist-Care arm

"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."

Trial Locations (1)

28040

Fundación Jimenez Díaz, Madrid

All Listed Sponsors
lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT06159894 - "Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of HIV Units." | Biotech Hunter | Biotech Hunter